sterna Biologicals GmbH & Co. KG is a clinical-stage immunology company developing novel treatments for type 2 chronic inflammatory diseases such as asthma and ulcerative colitis. By targeting GATA-3, a master transcription factor playing a central role in regulating Th1- and Th2-driven inflammatory mechanisms, sterna’s proprietary DNAzyme-based drug candidate hgd40 can intervene with upstream inflammatory processes to address related diseases more effectively. While existing treatment options often only address one inflammatory mediator, hgd40 broadly antagonizes several inflammatory processes and mediators at the same time.

We have successfully demonstrated that GATA-3 downregulation could provide for a truly novel, first-in-class, broad-spectrum, non-steroidal anti-inflammatory therapy. With safe and efficacious GATA-3 specific novel immunomodulating therapies, we can support millions of patients suffering from chronic type 2 inflammatory diseases – the most significant cause of death in the world.